VRDN Q4 2020 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54,000-93.9% YoY

Gross Profit

-$15M-28148.1% margin

Operating Income

-$91M-167774.1% margin

Net Income

-$91M-168040.7% margin

EPS (Diluted)

$-23.07

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$131M

Total Liabilities

$11M

Stockholders' Equity

$120M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54,000	$880,000	-93.9%
Gross Profit	-$15M	-$6M	-174.5%
Operating Income	-$91M	-$10M	-799.6%
Net Income	-$91M	-$10M	-796.8%

Revenue Segments

Collaboration Revenue

$54,000100%